Skip to main content

Peptide Profile

GHRP-6

Growth Hormone Releasing Peptide-6

GHRP-6 (growth hormone-releasing peptide 6) is a synthetic hexapeptide GH secretagogue that acts as an agonist at the ghrelin receptor (GHS-R1a) in pituitary somatotrophs and the hypothalamus, stimulating GH release through a…

GH / IGF AxisUnder clinical reviewResearch Only
Used forperformance
Half-life
15-60 minutes
Routes
subcutaneous, intranasal

Educational research information — not medical advice. Review primary sources and consult a qualified professional before any decision.

Educational research tools — not medical advice.

Overview

What GHRP-6 is

About GHRP-6

Ghrelin receptor agonist; stimulates pituitary GH release and increases appetite via hypothalamic ghrelin pathways

GHRP-6 (growth hormone-releasing peptide 6) is a synthetic hexapeptide GH secretagogue that acts as an agonist at the ghrelin receptor (GHS-R1a) in pituitary somatotrophs and the hypothalamus, stimulating GH release through a mechanism that is synergistic with but distinct from endogenous growth hormone-releasing hormone (GHRH). Like other GHRP-class peptides, it engages hypothalamic arcuate nucleus circuits to potentiate GHRH-driven GH pulses and partially suppress somatostatin inhibitory tone; it was among the first GHRP-class compounds characterized pharmacologically and has been used extensively as a research tool for probing the GH secretory axis. Clinical studies have demonstrated dose-dependent GH release following GHRP-6 administration in human subjects, and the GHRP pharmacological class has been characterized across multiple studies documenting pituitary and hypothalamic mechanisms of action. GHRP-6 is not FDA-approved for any indication; it has been studied as a pharmacological tool and provocative GH stimulation agent but has not been evaluated for safety or efficacy in performance enhancement or muscle building outside research protocols. GHRP-6 research contexts: GHRP-6 has been studied via subcutaneous and intravenous administration in human and animal research. GHRP-6 produces a pronounced appetite stimulation effect (a direct ghrelin-mimetic consequence) that is stronger than what is observed with more selective GHRPs such as ipamorelin; this characteristic is relevant to research contexts studying GH secretion alongside energy intake regulation. GHRP-6 vs GHRP-2: both are non-selective GHRPs producing GH alongside cortisol and prolactin co-stimulation, but GHRP-6 is noted for more pronounced ghrelin-like appetite stimulation, while GHRP-2 produces greater GH output per unit dose in some comparative studies. Neither offers the selectivity profile of ipamorelin, which emerged from subsequent GHRP research specifically to reduce off-target hormonal effects. GHRP-6 is administered by subcutaneous injection in research contexts. Providers offering GHRP-class secretagogues are listed in the PeptideBase directory.

GHRP-6 Benefits & Research Areas

GH release via GHS-R1a agonism — synergistic with GHRHpronounced appetite stimulation (ghrelin-mimetic effect)muscle recovery and GH pulse amplificationco-stimulation of cortisol and prolactin — less selective than ipamorelin

Research Signals

Commonly researched in the context of

High Training Load

Population research notes

18–2930s40s50+

These signals reflect research interest areas, not treatment indications.

Pharmacokinetics

GHRP-6 half-life calculator

Compound & timing

Half-lifefrom PeptideBase data
Source: "15-60 minutes" · GHRP-6 (PeptideBase)
to show amount remaining
1 h
0%25%50%75%100%012.13.14.25.2time since dose (h)
Plasma decay curve for GHRP-6: 6.3% to 50% remaining at 1 h after the dose.
range (15-60 minutes)slower half-life
6.3%–50%remaining in plasmaat 1 h after the dose
Half-life
15 – 60 min
~97% cleared after
5 h

Model: single-dose, first-order (single-compartment) estimate. Real clearance is multi-compartment and varies by individual and route.

The Research

What the evidence says about GHRP-6

Research Evidence

based on 1 study · dated evidence base — most recent 1997

Regulatory Status

Availability Status
Research Only
FDA Status
Under clinical review

Hexapeptide GH secretagogue. No FDA approval. Listed on the FDA Category 2 'significant safety risks' bulk-substances list (503B designation, added September 2023). WADA prohibited. Historical Phase 2 trials (Theratechnologies) but abandoned. Research chemical.

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Research Sources

1 source cited · 1 weak

1 Review

  • Growth hormone-releasing peptides

    European Journal of Endocrinology · 1997

    This review summarizes evidence from human and animal studies that GHRPs including GHRP-6 potently stimulate GH secretion via specific receptors at the pituitary and hypothalamic levels, with dose-related effects after intravenous, subcutaneous, intranasal, and oral administration, and synergistic GH release when combined with GHRH.

    ReviewTheoreticalPMID 9186261

GHRP-6 Side Effects & Safety Considerations

No FDA-approved label for this compound. Cautions below are extrapolated from its mechanism/drug class — investigational; educational only.

Absolute contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Common monitoring markers in research protocols

GHRP-6 produces stronger cortisol and prolactin stimulation than selective GH peptides. Research protocols measure IGF-1 for GH axis response and baseline cortisol. Glucose markers are standard given GH's effect on insulin sensitivity.

IGF-1Fasting glucoseHbA1cCortisolInsulin

Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.

Known Interactions

1 noted

Pharmaceutical interactions are noted for research awareness. Always consult your prescriber before combining GHRP-6 with any medication.

Use With Caution1
CorticosteroidsPharmaceutical
Emerging

Research notes that GHRP-6 stimulates cortisol and ACTH release via the HPA axis. Combined use with corticosteroid medications may affect glucocorticoid regulation. Consult your prescriber before combining.

Broglio F et al. (2002) GHRP-6 and HPA axis stimulation. J Endocrinol Invest; Ghigo E et al. (1997) GH secretagogues and the HPA axis. Metabolism

These interactions reflect published research and are provided for educational purposes only. This is not medical advice. Consult a qualified healthcare professional before combining any compounds or medications.

Third-party testing data

Limited testing data (1 verified result)

We only show a verified-testing signal once at least 3 independent lab results are on file. Below that, we show what we have without implying a confidence signal.

PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Certificates of Analysis

5 COAs on record for GHRP-6

PeptideBase reports these lab-published figures and does not itself test, endorse, or certify any product. Confirmed by lab results were matched against the issuing laboratory's own records — either the lab served the document, or its own hosted copy matches ours byte for byte. For every other result the badge states what is known about the lab: that it can be checked and no result is recorded yet, that it can't be checked, or that we have not reviewed it.

PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Frequently Asked Questions — GHRP-6

GHRP-6 (growth hormone-releasing peptide 6) is a synthetic hexapeptide GH secretagogue that acts as an agonist at the ghrelin receptor (GHS-R1a) in pituitary somatotrophs and the hypothalamus, stimulating GH release through a mechanism that is synergistic with but distinct from endogenous growth hormone-releasing hormone (GHRH). Like other GHRP-class peptides, it engages hypothalamic arcuate nucleus circuits to potentiate GHRH-driven GH pulses and partially suppress somatostatin inhibitory tone; it was among the first GHRP-class compounds characterized pharmacologically and has been used extensively as a research tool for probing the GH secretory axis.

GH release via GHS-R1a agonism — synergistic with GHRH, pronounced appetite stimulation (ghrelin-mimetic effect), muscle recovery and GH pulse amplification, co-stimulation of cortisol and prolactin — less selective than ipamorelin.

Research on GHRP-6 primarily documents effects related to GH release via GHS-R1a agonism — synergistic with GHRH and pronounced appetite stimulation (ghrelin-mimetic effect) and muscle recovery and GH pulse amplification and co-stimulation of cortisol and prolactin — less selective than ipamorelin. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.

For GHRP-6, it is designated for research use only. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

33 providers in the directory currently offer GHRP-6.

Across 20 research vendors tracked on PeptideBase, GHRP-6 has a median price of about $4.60 per mg, typically ranging $3.18–$6.65 per mg. This reflects research-use vendor pricing, not clinical or prescription costs.

GHRP-6 is featured in the following research stacks on PeptideBase: CJC-1295 + Ipamorelin + GHRP-6: GH Secretagogue Max.

Access

How to get GHRP-6

Market Pricing

20 vendors
$3.18/mgBudget
$4.60/mgMedian
$6.65/mgPremium
$3.18
$4.60
$6.65

Price per mg varies by quantity, vendor type, and formulation. Research use only.

Data verified August 2026 · GHRP-6 price intelligence

Where to buy GHRP-6

33 providers
20 Clinics12 Online Vendors1 Physician39 in stock

Research stacks

Browse all →

Questions to ask your provider

Stay updated on GHRP-6 providers

New providers added weekly — delivered to your inbox.

Weekly research digest. No spam. Unsubscribe anytime.

Last updated

Cite this page

Data last updated August 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). GHRP-6 — Per-mg Price Benchmark. Retrieved September 11, 2026, from https://peptidebase.io/peptides/ghrp-6

Free newsletter

The Peptide Research Digest

Weekly analysis on providers, sourcing and compounds — from the team behind PeptideBase.

No spam. Unsubscribe anytime. Privacy policy.